Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...

When we turn our attention to emerging global threats, we know what to expect: grim statistics, dire predictions, and—perhaps worst of all—disturbing revelations that no preventive or corrective ...

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

Results for talquetamab presented at the 64th American Society of Hematology Annual Meeting and Exposition showed that about 70% of patients with multiple myeloma had responses. More than 70% of ...

Please provide your email address to receive an email when new articles are posted on . Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory ...

“Patients did great” with a four-drug regimen for multiple myeloma, an expert told CURE®. Patients with newly diagnosed multiple myeloma treated with the four-drug combination of Sarclisa (isatuximab) ...

An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...

Journal of the Royal Statistical Society. Series C (Applied Statistics), Vol. 18, No. 3 (1969), pp. 221-228 (9 pages) Very often the object of experimental development programmes is the optimization ...